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MILESTONES IN TRANSPLANTATION 
THE STORY SO FAR: 
by 
Thomas E. Starzl, M.D., Ph.D. 
NOTE: The milestones in the following material were discussed 
at a historical concensus conference held at the University of 
California, Los Angeles (UCLA) to which 11 early workers in 
transplantation were invited: Leslie B. Brent (London), Roy 
Y. Calne (Cambridge, Eng), Jean Dausset (Paris), Robert A. 
Good (St. Petersburg, Fla) , Joseph E. Murray (Boston), Norman 
E. Shumway (Palo Alto), Robert S. Schwartz (Boston), Thomas E. 
Starzl (Pittsburgh), Paul I. Terasaki (Los Angeles), E. 
Donnall Thomas (Seattle), Jon J. van Rood (Leiden). Each man 
provided personal reflections which have been published in a 
special issue of the World Journal of Surgery (Volume 24:755-
843, 2000). However, the ultimate objective was to reach 
consensus on the key historical discoveries prior to 1975 that 
eventually allowed clinical transplantation to become a 
feasible and practical form of therapy. Carl Groth of 
Stockholm was invited to be the Chairman for these consensus 
deliberations, and to prepare the executive summary (Groth et 
al, 2000). Concensus landmarks in the summary were restricted 
to those made at least a quarter of a century ago. Although 
advances in the 1975-2000 period were not formally reviewed, 
the ones alluded to here appear destined for milestone status. 
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The concept of transplanting animal or human tissues and 
organs to patients is almost as old as recorded history 
(Bhandari and Tewari, 1997). However, the first enduring 
contribution was the technology of blood vessel anastomosis 
developed by Carrel (1902) (see Table 1). Carrel recognized 
that transplanted organ allografts and xenografts were not 
permanently accepted, although he did not know why. 
THE TECHNICAL CHALLENGE 
The Kidney 
Attempts at clinical renal xenotransplantation by 
vascular anastomoses were undertaken at the beginning of the 
twentieth century in France and Germany using pig, sheep, 
goat, and subhuman primate donors. None of the kidneys 
functioned for long, if at all, and the unmodified human 
recipients died a few hours to 9 days later. No further 
clinical xenotransplantations were tried again 
chimpanzee (Reemstsrna et aI, 1964) and baboon 
xenografts were transplanted to human recipients 
immunosuppression (Starzl et al, 1964d). 
until 
kidney 
under 
The first known attempt at transplantation of an organ 
allograft was reported from Kherson (the Ukraine) in 1936 by 
Yu Yu Voronoy (1937); an English translation of the article 
has been provided by Hamilton and Reid (1984). The kidney, 
which was removed from a cadaver donor never functioned. This 
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was not surprising in view of multiple adverse factors: ABO 
incompatibility between the donor and recipient, a 6 hours 
delay at room temperature between donor death and kidney 
removal, and the recent suicide attempt of the recipient by 
mercury ingestion. In 1951, systematic clinical trials of 
kidney allotransplantation in unmodified human recipients were 
undertaken in France by Kuss, Teinturier and Milliez (1951), 
Dubost et al (1951), and Servelle, Soulie, and Rougeulle 
(1951) . Most of the kidneys were obtained from criminals 
immediately after their execution by the guillotine, and some 
briefly excreted urine. 
The first live donor kidney transplantation was performed 
in Paris by Michon et al (1953), using the extraperi toneal 
pelvic procedure developed by Kuss. This mother-to-son 
transplantation resulted in prompt kidney function that 
continued for three weeks before the allograft was rejected by 
the unmodified recipient. Kuss's procedure has been used 
worldwide ever since with an outstanding record of safety and 
reliability. 
In the meanwhile, 9 kidney allotransplantations were 
performed between 30 March 1951 and December 3, 1952 in 
patients whose pre- and post-transplantation dialysis was at 
the Peter Bent Brigham Hospital ("The BrighamH) in Boston 
(Hume et al, 1955). In the first of these operations, 
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performed by L. H. Doolittle in Springfield, Massachusetts, 
the allograft was transplanted to the vacated renal fosa of 
the recipient after removal of the native organ. The next 8 
transplantations were performed at the Brigham. All 8 of 
these allografts were placed by David Hume in the recipient 
anterior thigh. Some of the recipients received adrenal 
cortical steroids, and one of the transplanted kidneys 
produced urine for 5 months. 
In December 1954, kidney transplantation from an 
identical twin donor recipient was carried out by Joseph E. 
Murray at the Brigham Hospital in Boston (Murray, Merrill, and 
Harrison, 1955; Merrill et aI, 1956). It was known from 
earlier research by plastic surgeons that s kin grafts from 
identical twins were not rejected. To test genetic identity, 
reciprocal skin grafting was carried out prior to the kidney 
transplantation. Despite 82 minutes of warm ischemia, the 
isograft functioned immediately and for the next 25 years, 
until the death of the recipient from atherosclerotic coronary 
artery disease. Although the identical twin kidney 
transplantations did not provide fundamental new information 
about transplantation immunology, the cases exemplified the 
potential power of transplantation. 
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The Extrarenal Organs 
Using vascular surgical techniques, animal research in 
transplantation was most highly focused on the kidney for most 
of the first half of the 20th century. The extrarenal vacuum 
rapidly was filled between 1958-1960 with the development in 
several laboratories of canine models with which to study all 
of the intra-abdominal and thoracic organs. Although each 
organ presented specific technical and physiologic issues, the 
core problems of immunosuppression, tissue matching, and 
allograft preservation eventually were worked out mainly with 
the kidney or/and the liver and applied to other organs with 
minor modifications. 
THE SEMINAL TURNING POINTS 
The modern history of transplantation could be written 
from the vantage point of the first successful use in humans 
of allografts of the various organs and of bone marrow (Table 
2). However, a more accurate and complete picture can be 
obtained by reviewing how it was learned to harness 
destructive immunity enough to allow allograft survival. 
After Medawar's demonstration that rejection is an immune 
reaction (1944), the feasibility of transplanting allografts 
hinged on 2 observations. The first was the discovery in 1953 
by Billingham, Brent and Medawar (1953, 1956) that chimerism-
associated neonatal tolerance could be induced in intrauterine 
and neonatal mice by the infusion of donor hematolymphopoietic 
6 
cells (i.e. splenocytes and bone marrow). The second seminal 
turning point was the recognition that human organ allografts 
were inherently tolerogenic when transplanted to 
immunosuppressed recipients (Starzl, Marchioro, and Waddell, 
1963b) . 
Unfortunately, these 2 sets of observations led to a Y in 
the road beyond which successful engraftment of bone marrow 
was explained by donor leukocyte chimerism-dependent 
mechanisms, whereas organ engraftment was attributed to 
chimerism-independent mechanisms. This egregious error 
precluded genuine insight into the immunology of 
transplantation for nearly 3 decades and resulted in a 
systematic misinterpretation of research studies in 
transplantation (Starzl, 2000). That a mistake of such 
magnitude could have been perpetuated for so long without a 
single challenge in the scientific literature is truly 
remarkable. This can be explained in part by the primitive 
state of immunology (see next section) at the time the false 
dogma became imbedded in the scientific literature and 
textbooks. 
THE ASCENDENCY OF IMMUNOLOGY 
The foundation of immunology had been laid at the turn of 
the century by the piecemeal discovery of the different 
components of the immune response and of the role of immunity 
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in the defense against infectious disease. This wave of 
advances resulted in a large proportion of the first 30 Nobel 
prizes (Table 1). The big leaps were succeeded by a period of 
"consolidation" that was reflected by a gap of 30 years 
between the 1930 Nobel prize for Landsteiner's discovery of 
ABO groups and the 1960 prize which was awarded to Burnet and 
Medawar (see Table 1). Burnet with Fenner (1949) had 
initially postulated that an individual produced antibodies 
only to those antigens to which (s)he had been exposed. Over 
the next decade, this clonal selection hypothesis was 
validated and extended by Burnet (1959) to cellular immunity, 
thus providing a conceptual framework for the ontogeny of the 
immune system as well as for its function. 
An important supporting strut in Burnet's hypotheses was 
the earlier study by Owen (1945) of freemartin cattle, the 
bovine equivalents of human fraternal twins. Owen observed 
that permanent hematopoietic chimerism developed reciprocally 
in calves whose placentas had fused, thereby allowing 
intrauterine circulatory exchange. Working with Medawar, 
Anderson et al (1951) subsequently showed that these cattle 
also had reciprocal tolerance to skin grafts. The authors 
speculated that actively acquired tolerance could be induced 
deliberately by mimicking the conditions of cross circulation. 
When the neonatal tolerance experiments of Billingham, Brent, 
and Medawar (1953,1956) upheld the prediction, the 
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observations were viewed as formal proof of the clonal 
selection theory of Burnet. 
THE BILLINGHAM-BRENT-MEDAWAR EXPERIMENTS 
In the original Billingham-Brent-Medawar experiments 
(1953), acquired tolerance to skin allografts was induced in 
fetal and neonatal mouse recipients whose immunologically 
immature immune system was unable to reject the infused 
splenocytes from adult donors. 
marrow cells were used (1956). 
In later experiments, bone 
The inoculated animals that 
survived to adult life had circulating donor leukocytes and 
developed specific non-responsiveness to donor strain skin 
allografts, while evolving normal reacti vi ty to third party 
grafts. By 1957, however, it had been learned that the 
engraftment of immunocompetent donor leukocytes in 
immunologically defenseless recipients caused graft-versus-
host disease (GVHD) that was avoidable or controllable only 
when there was a close genetic relationship between donor and 
recipient (i. e. a good "tissue match") (Billingham and Brent, 
1957 and 1959; Simonsen, 1957). 
In a logical extension of these experiments, adult mice 
were preconditioned for bone marrow transplantation with 
supralethal total body irradiation [TBI]). With engraftment 
of the donor bone marrow cells in these animals, the result 
was the same in principle as that achieved a decade later with 
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human bone marrow transplantation to cytoablated recipient. 
However, the requirement for a good tissue match in mice 
(Trentin, 1956) applied equally to humans (Mathe et aI, 1963; 
Gatti et aI, 1968; Bach et aI, 1968). Mathe was the first to 
achieve prolonged survival after engraftment of allogeneic 
human bone marrow cells, but in spite of good 
histocompatibili ty between multiple familial donors and the 
cytoablated recipient, chronic graft-versus-host disease 
(GVHD) developed in this patient and caused his death after 2 
years. Finally, in 1968, bone marrow cells were successfully 
transplanted from familial donors into 2 recipients whose 
immune deficiency diseases made cytoablation unnecessary 
(Gatti et aI, 1968; Bach et aI, 1968). 
alive and well 32 years later. 
Both patients are 
IMMUNOSUPPRESSION FOR ORGAN TRANSPLANTATION 
Once rejection was identified by Medawar (1944) as an 
immunological event, weakening the recipient response with TBI 
or with immunosuppressive drugs, became a logical strategy for 
mitigating or preventing the immune reaction. Cortisone, 
which did not depress bone marrow, was the first drug to 
prolong the survival of rabbit skin allografts (Billingham, 
Krohn, and Medawar, 1951), but the effect was modest. In 
contrast, observations in chickens reported by Cannon and 
Longmire (1952) were of exceptional significance. However, 
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the importance of this work was not recognized until many 
years later. 
In control experiments, Cannon and Longmire showed that 
freshly hatched chicks permanently accepted skin allografts 
from different adult breeds in 6% of experiments. When a 
course of cortisone treatment was given, this incidence rose 
to over 20% without an increased mortality. The critical 
observation was that the skin allograft survival was of 
lifetime duration: i.e. continued after discontinuance of the 
steroid course. This finding presaged the discovery in Denver 
a decade later that organs were inherently tolerogenic in 
patients treated with azathioprine and dose-maneuverable 
prednisone (Starzl, Marchioro, and Waddell, 1963b). Because 
the Cannon/Longmire studies had been long since passed over, 
however, they did not alter the pessimistic attitudes 
prevalent at the time about the feasibility of clinical organ 
transplantation. 
Total Body Irradiation (TBI) 
Instead, it was widely believed by the late 1950s that 
successful organ transplantation would not be possible without 
establishing donor leukocyte chimerism by the concomitant or 
preceding engraftment of donor bone marrow cells as had been 
shown to be feasible in cytoablated mice (Main and Prehn, 
1955; Trentin, 1956). In practice, this approach proved to be 
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impossible in large outbred animals (Hume et ai, 1960). With 
the dog model, only a single irradiated beagle recipient 
survived for as long as 70 days following combined bone marrow 
and kidney transplantation (Mannick et ai, 1959). 
Despite this discouraging record in animals, Murray et al 
attempted the· combined procedure at the Peter Bent Brigham 
Hospital (Boston) in 2 TBI-conditioned patients, both of whom 
died in less than a month. The next 10 human recipients in 
this trial were conditioned in 1958-60 with sublethal TBI, 
followed by kidney transplantation alone (Murray et ai, 1960 
and 1962). All but one of the patients also died within one 
month. In the exceptional case, however, the irradiated 
recipient of a fraternal twin kidney survived for more than 20 
years before dying of a malignant tumor. It was the first 
example in the world in any species including humans of 
successful organ transplantation from a genetically non-
identical donor. 
It was suspected initially that placental fusion and 
cross circulation between the twins may have occurred in utero 
(as with Owen's freemartin cattle). The same reservation 
pertained to a second extended survival following fraternal 
twin kidney transplantation in Paris 5 months later (Hamburger 
et ai, 1959). In the succeeding 3 years, however, the issue 
was settled by 4 more examples of survival > one year in 
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Paris. Two of these irradiated patients received kidneys from 
non-twin family members (Hamburger et al, 1962). The kidneys 
in the other 2 cases were from non-related donors (Kuss et al, 
1962) (Table 3). Because none of the 6 kidney allograft 
recipients who had > one year survival had been given adjunct 
donor bone marrow cells, it was concluded that donor leukocyte 
chimerism was not a necessary condition for successful kidney 
transplantation. 
Pharmacologic Immunosuppression 
Because the failure rate using TBl was overwhelming, the 
prospects for developing kidney transplantation as a clinical 
service remained grim until the end of 1962. A sea change 
began with the testing of drugs whose myelotoxicity initially 
prompted their use as a substitute for TBl. In 1963, Willard 
Goodwin of Los Angeles belatedly reported a case of a mother-
to-daughter kidney transplantation that had been carried out 
in September 1960, after first producing severe bone marrow 
depression with large doses of methotrexate and 
cyclophosphamide. During the 143 days of survival, the 
recipient developed several rejections that were reversed with 
prednisone (Goodwin et al, 1963). 
Although this was the first example of extended survival 
of a human kidney recipient without the use of TBl, the case 
did not significantly impact the field because its existence 
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was not generally known. In the meanwhile, it had been 
learned in studies of rabbit skin transplantation (Schwartz 
and Dameshek, 1960; Meeker et ai, 1959) and of kidney 
transplantation in dogs (Caine 1960, 1961a; Zukoski et ai, 
1960) that the drug 6-mercaptopurine (6MP) and its imidizole 
derivative azathioprine, were immunosuppressive at 
submyelotoxic doses. Both agents permitted only about 5% long 
term survival of canine kidney allografts (Murray et ai, 
1962), but the transplanted kidneys in some of the long-
surviving animals continued to function long after 
discontinuance of immunosuppression (Pierce and Varco, 1962; 
Zukoski and Calloway, 1963; Starzl, 1964a; Murray et ai, 
1964). The observation was reminiscent of the finding in 
newly hatched chicks treated with a short limited course of 
cortisone that had been described a decade earlier (Cannon and 
Longmire, 1952). 
Realizing that neither 6-MP nor azathioprine alone would 
permi t more than an occasional clinical success, Caine and 
Murray (1961b) tested azathioprine in combination with other 
myelotoxic drugs at the Brigham canine laboratory. Prompted 
by the personal communication from Goodwin about the effect of 
steroid therapy (Murray, 1999 [see earlier]), prednisone also 
was added to azathioprine. When the azathioprine-prednisone 
combination appeared to be no more effective than azathioprine 
alone (CaIne, 1961a, CaIne et aI, 1962), the decision was made 
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to use azathioprine with the myelotoxic agents azaserine and 
actinomycin for the Boston clinical trials. Only one of the 
first 10 drug-treated kidney recipients survived. The 
exceptional patient received a non-related kidney on April 5, 
1962, and remained dialysis-free for 17 months until the 
allograft was lost to chronic rej ection. Thus, this patient 
became the seventh one-year kidney allotransplant survivor in 
the world. More importantly, he was the first to achieve this 
milestone without TBI (Table 3). 
With the late rate of success, however, kidney 
transplantation was still viewed with pessimism. This was 
relieved by 2 observations at the University of Colorado, 
first in canine kidney recipients and then in a series of 10 
consecutive human cases compiled in 1962-63. The addition of 
high doses of prednisone to baseline therapy with azathioprine 
resul ted not only in reversal of established rej ection, but 
also in the variable induction of donor specific tolerance 
(Starzl, Marchioro, and Waddell, 1963b). Nine of the 10 human 
recipients had prolonged survival and 2 remain alive today 
with excellent function of their original grafts in their 38 th 
post transplant year. These 2 patients (cases 2 and 3 in the 
original series), who bear the longest continuously 
functioning allografts in the world, have been free of all 
immunosuppression for 5 and 36 years respectively. 
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These results, and especially the easily taught treatment 
principles with which they were accomplished, fostered a 
whirlwind of activity in the United States and Europe. While 
dozens of new kidney transplant centers were established, the 
mechanisms by which the allografts had been "accepted" 
remained unknown. However, the conclusions that the kidney 
allografts had induced variable donor specific tolerance, and 
that engraftment depended on alterations in the transplanted 
organ plus a loss of specific responsiveness by the recipient 
(Starzl, Marchioro, and Waddell, 1963b; Starzl, 1964a) has 
stood the tests of time and of experimental verification. 
These conclusions continued to generate controversy for 3 
decades. Commenting on mechanisms, Medawar (1965) suggested 
that a progressive replacement of the vascular endothelium of 
the graft vessels by endothelium of host origin may have been 
made possible by weakening the allograft reaction with 
immunosuppression. Neither this hypothesis nor the suggestion 
that "a protective" host antibody had come to cover the 
endothelial layer (attributed to Calne by Medawar, 1965) has 
proved to be correct. 
The enigmatic phenomena of the reversal of rejection and 
the development of variable donor specific tolerance observed 
after kidney transplantation were soon demonstrated with other 
organs. Furthermore, canine recipients of orthotopic liver 
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allografts 
azathioprine 
self-induced tolerance under short 
than 
term 
renal therapy much more frequently 
allografts (Starzl et al, 1965a). Soon thereafter, examples 
of spontaneous engraftment and self-resolving rejection crises 
in the absence of treatment were reported following liver 
transplantation in untreated outbred pigs (Cordier et al, 
1966; Peacock and Terblanche, 1967; Calne et al, 1967). 
Sponstaneous tolerance has since been demonstrated in rats 
(Kamada, Brons, and Davies, 1980; Zimmerman et al, 1984) and 
mice (Qian et al, 1994). 
Eventually, it was shown that heart (Corry, Winn, and 
Russell, 1973; Qian et al, 1994) and kidney allografts 
(Russell et al, 1978) also could self-induce donor-specific 
tolerance in selected mouse strain combinations. Exhaustion 
and deletion of an antigen-specific clone was one of the 
mechanisms proposed for allograft acceptance as early as 1964 
and again in 1969 (Figure 1), but this was difficult to defend 
in the absence of chimerim. The failure to evolve an 
intellectual framework with which to explain organ engraftment 
contrasted with bone marrow transplantation in which the 
association of tolerance with donor leukocyte chimerism was 
readily apparent. 
Thus, organ transplantation became disconnected from a 
scientific base, creating an image that was judged at times to 
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be dubious scientifically, ethically and practically. A 
widely expressed opinion was that chronic immunosuppression 
would lead inevitably to lethal infectious complications 
and/or the development of malignant tumors (Figure 2). These 
complications did, in fact, prove to be common. Infection was 
exemplified by the cytomegalovirus (CMV) , which normally has 
low pathogenicity, but which has been responsible for many 
deaths as a co-infection with post-transplantation 
Pneumocystis carinii. De novo neoplasms, and particularly the 
Epstein Barr virus-associated B cell malignancies, were 
prototype examples of the loss of tumor surveillance (Starzl, 
1969b). As it turned out, these problems were manageable. 
Antilymphoid Strategies 
Successful kidney transplantation was first accomplished 
several years before the lymphocyte had any known function, 
and almost a decade before the distinction between T- and B-
lymphocytes was made. After Gowan's studies in rats 
demonstrated the defects in the immune response caused by 
lymphoid depletion with thoracic duct drainage (TOO) (McGregor 
and Gowans, 1963, 1964), TOO was used in Stockholm in 1963 and 
subsequently to precondition human kidney recipients 
(Franksson and Blomstrand, 1967). Although moderately 
effective, TOO was inconvenient and expensive. When Woodruff 
and Anderson (1963) added antilymphocyte serum (ALS) to TOO, 
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the effects were additive, but this combination was never used 
clinically. 
In 1966, heterologous antilymphocyte globulin (ALG) was 
introduced clinically for lymphoid depletion (Starzl et aI, 
1967) . In preclinical studies, horse anti-dog antilymphocyte 
serum (ALS) was raised and the active component was shown to 
be a gamma globulin moiety (Iwasaki et aI, 1967). After 
demonstrating that the refined horse anti-dog ALG inhibited or 
reversed kidney and liver rejection in dogs, horse anti-human 
ALG was raised and given to human kidney recipients as a 
short-term adjunct to azathioprine and prednisone. After the 
"triple drug" therapy was shown to be effective in the kidney 
trial, the same treatment was used in 1967 for the first 
successful liver transplanatations (Starzl et aI, 1968a). 
Within 24 months after the first successful liver 
replacement, many extrarenal transplant programs (i. e. heart, 
lung, and pancreas) were begun, using triple drug therapy. 
Al though isolated successes were recorded (Table 2), most of 
these new programs closed because of the high mortality. 
Nevertheless, ALG played an important role in the first 
successful extrarenal organ transplant procedures, and served 
as the therapeutic model for strategies using the more 
standardized antibody preparations made possibly by the 
hybridoma technology of Kohler and Milstein (1975). 
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OKT3, a monoclonal antibody directed against all T 
lymphocytes was introduced clinically in the early 1980s 
(Cosirni et al, 1981) and is still part of the 
immunosuppressive armamentarium. Other monoclonal antibody 
preparations have been developed more recently, some of which 
are humanized hybrids and directed at such diverse targets as 
T-cell subsets, adhesion molecules, and receptors for T cells 
or interleukin-2 (1L-2). Their diversity notwithstanding, the 
use of all of the monoclonal antibodies is guided by the same 
treatment principles that were developed with the crude ALG. 
T-Cell Direoted Drugs 
Borel et al (1976) showed that cyclosporine depressed 
cellular immunity by acting with relative specificity on T 
lymphocytes without depressing the bone marrow and without 
obvious toxicity to other organs. Borel et al also reported 
that the new drug prolonged skin allograft survival in mice, 
rats, and guinea pigs. Kostakis et al (1977), Calne and White 
(1977), and Green and Allison (1978) then demonstrated that 
cyclosporine could prevent or delay heart, kidney, liver, or 
pancreas rejection in rats, rabbits, dogs, and pigs. After 
cyclosporine was introduced clinically, the dose-limiting 
nephrotoxicity of the drug became apparent as well as its 
neurotoxicity, diabetogenicity, cosmetic side effects, and 
propensity to induce B cell lymphomas (Calne et al, 1978, 
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1979). At lower doses, and in combination with prednisone 
(Starzl et al, 1980), the prognosis with transplantation with 
all kinds of organs, and especially the liver (Starzl et al, 
1981), was dramatically improved (Figure 3) . 
. Tacrolimus was first used clinically as a replacement for 
cyclosporine in patients who were intractably rejecting liver 
allografts (Starzl et aI, 1989a; Fung et aI, 1990). When the 
drug was found to rescue >75% of rejecting hepatic allografts 
and other kinds of rejecting organs, trials were began using 
tacrolimus as the baseline agent from the outset (Todo et aI, 
1990) . Tacrolimus did not have cyclosporine's cosmetic side 
effects, but the nephrotoxicity, neurotoxicity, and 
diabetogenicity profiles were similar. As with cyclosporine, 
these problems were dose-related and manageable by using 
tacrolimus in combination with prednisone or in more complex 
drug cocktails. Survival of various kinds of grafts and their 
recipients was improved (Figure 3) and it became possible for 
the first time to offer intestinal transplantation as a 
clinical service (Todo et al, 1992) . Most recently, 
tacrolimus has been combined with rapamycin, with 
unprecedented control and prevention of rejection. 
ORGAN PRESERVATION 
Very little research had been done on preservation of 
organs at the time clinical kidney transplantation suddenly 
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and unexpectedly became a widely used form of treatment in the 
early 19605. Total body hypothermia of live donors was used 
initially to minimize ischemic injury to the excised kidney 
(Starzl et aI, 1963a), but this potentially dangerous practice 
was promptly supplanted by infusion of chilled fluids into the 
allograft renal artery immediately after donor nephrectomy 
(Starzl, 1964b). Intravascular cooling of liver allografts 
with chilled lactated Ringers solution had been developed much 
earlier in canine liver transplant experiments and had 
dramatically increased the chance of survival (Starzl et aI, 
1960) . Today, intravascular cooling derived from the in situ 
techniques of Marchioro et al (1963) remains the first step in 
the preservation of all cadaveric organs. 
Two basic strategies for extending organ graft survival 
after initial cooling also were developed with kidneys and 
livers, and applied to other organs. In one, ex vivo 
perfusion techniques were used to simulate normal physiologic 
conditions as pioneered by Carrel and Lindberg (1938). Using 
blood for priming, the technology was modified by Ackerman and 
Barnard (1966). Because these perfusion methods were too 
complex for general use, Belzer, Ashby and Dunphy (1967) 
developed a simplified asanguinous perfusion technique, which 
eventually was a.bandoned in favor of the second option of 
"slushU preservation. 
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Slush preservation consists of intravascular infusion 
with chilled fluids, followed by immersion of the organ in the 
fluid and simple refrigeration. Collins, Bravo-Shugarman, and 
Terasaki (1969) replaced the original lactated Ringers 
solution with a perfusate that resembled the electrolyte 
composition of intracellular fluid. Renal allograft 
preservation with the "Collins solution" was reliable for at 
least a day, and preservation of the liver was adequate for 
approximately 6 hours. Nearly 20 years passed before the 
advent of the University of Wisconsin (UW) solution allowed 
the safe preservation of livers for 24 hours (Kalayoglu et aI, 
1988, Todo et aI, 1989) with a doubling of the safe time for 
kidney preservation. The UW solution made the exchange of 
organs between different cities or countries a reality. 
Before 1980, cadaveric organ procurement and kidney 
procurement were essentially synonymous. Wi th the emergence 
of extrarenal organ transplantation, flexible techniques were 
developed with which the kidney, liver, heart, lung, pancreas, 
and even intestine could be removed separately or in 
combinations (Starzl et aI, 1984, 1987). These flexible 
techniques involve cooling of all organs in si tu and removal 
in a bloodless field, followed by ex vivo dissection. Taken 
together, the improvements in organ procurement and 
preservation have allowed the efficient use of donor organs, 
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an especially important advance in view of the world-wide 
shortage of essentially all kinds of allografts. 
IMMUNOLOGIC SCREENING 
Matching cadaveric donors against a list of prospective 
recipients was not possible until effective methods of organ 
preservation became available. Consequently, it had been 
predicted in the early 1960s that tissue matching and organ 
preservation would have to develop in parallel if long term 
engraftment of tissues and organs was to succeed with any 
degree of reliability and predictability. Instead, 
immunologic screening of donors and recipients played very 
little role in the developmental period of organ 
transplantation during the volatile period of 1959-1968. 
The Crossmatch Principle 
As it turned out, the greatest impact of pre-transplant 
immunologic screening has been the prevention of hyperacute 
rejection by observation of ABO compatibility guidelines and 
the routine use of the cytotoxicity crossmatch. 
ABO Incompatibility --- Hyperacute rejection was first 
observed more than 30 years ago when ABO-mismatched renal 
allografts were transplanted into patients who had preformed 
antigraft ABO isoagglutinins (Starzl, 1964c). After such 
kidneys were lost on the operating table, arteriograms of the 
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infarcted organs showed nonfilling of the small vessels. The 
gross findings correlated histopathologically with widespread 
thrombotic occlusion of the microvasculature. 
It was concluded that high-affinity ABO isoagglutinins in 
the recipient sera had bound to A or B antigens in the graft 
vessels and parenchymal cells. The guidelines formulated from 
this experience (Table 4) were designed to avoid such antibody 
confrontations (Starzl, 1964c). The ABO rules also apply to 
heart, liver, and other kinds of organ transplantation. 
However, not all organs placed in an environment made hostile 
by antigraft isoagglutinins meet the same fate. In addition, 
it was learned at an early time that the liver is more 
resistant to antibody attack than other organs (Starzl et al, 
1974). 
Preformed Antidonor Cytotoxins --- Hyperacute rejection 
of a kidney by an ABO compatible recipient was reported for 
the first time by Terasaki, Marchioro, and Starzl (1965). 
Terasaki's observation that the serum of the recipient of a 
live donor kidney contained preformed antigraft 
lymphocytotoxic antibodies was promptly confirmed in similar 
cases by Kissmeyer-Nielsen et al (1966) and by others 
(Williams et al, 1968; Starzl et al, 1968b). The evidence of 
a cause and effect relation in Terasaki's single first case 
was so clear that he recommended and immediately introduced 
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--- --------- ---
his now universally applied lymphocytotoxic crossmatch test 
(Terasaki, Marchioro, and Starzl, 1965; Patel and Terasaki et 
ai, 1969). 
Tissue Matching 
The importance of the genetically determined major 
histocompatibility complex (MHC) in determining the immune 
response to allografts was established at a very early time by 
investigations in inbred mice (Gorer, Lyman, and Snell, 1948; 
Snell 1948). The possibility of clinical tissue matching did 
not begin to emerge, however, until the discovery of the first 
human leukocyte antigen (HLA) (Dausset, 1958), and the 
discovery in the same year of anti leukocyte antibodies (soon 
shown to be HLA directed) in the sera of pregnant women (Van 
Rood, Eernisse, and van Leeuwen, 1958). 
The report in 1964 of the microcytotoxicity test, with 
which HLA antigens could be detected serologically with minute 
quantities of sera (Terasaki and McClelland, 1964) was a 
further critical development in moving forward with the 
detection and classification of the antigens. It was 
anticipated that long term organ engraftment would be 
achievable only with a high degree of donor/recipient HLA 
match, and that there would be a stepwise deterioration in 
outcome with every level of HLA mismatch. The importance of 
HLA matching was immediately fulfilled with bone marrow 
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transplantation, in which anything less than a perfect or near 
perfect match between the donor and recipient resulted in GVHD 
or else rejection of the graft (Mathe et aI, 1963; Bach et aI, 
1968; Gatti et al, 1968; Thomas et aI, 1975). 
Inexplicably at the time, Terasaki promptly recognized 
that kidney transplantation was not dependent on tissue 
matching. This was evident in a retrospective study of long 
surviving kidney recipients and their volunteer live donors 
(Starzl et al, 1965b). This was followed by a prospective 
trial in which kidney donors were selected on the basis of the 
best available HLA match for recipients who were treated with 
azathioprine and prednisone, with or without adjunct ALG 
(Terasaki et aI, 1966). Although HLA matched (zero 
mismatched) allografts had the best survival and function, no 
cumulative adverse effect of mismatching in the kidney 
recipients could be identified (Starzl et aI, 1970). This 
imprecise prognostic discrimination also pertained to cadaver 
kidney transplantation (Mickey and Terasaki, 1971) and has 
been evident in analyses up to the present time. The absence 
of a large and consistent matching effect unless there is a 
perfect or near perfect match has always been the same (Starzl 
et aI, 1997). Furthermore, the difference in clinical outcome 
with completely matched versus variably HLA-mismatched 
allografts has been surprisingly small. 
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Terasaki's observations of the University of Colorado 
kidney cases nearly 3 decades ago breathed life into the still 
struggling fields of liver, heart, and lung transplantation. 
It was a relief to know that the selection of donors with 
random tissue matching would not result in an intolerable 
penalty. A quarter of a century passed before it could be 
explained why HLA matching was critical for bone marrow, but 
not organ, transplantation (see next section). 
ALLOGRAFT ACCEPTANCE AND ACQUIRED 
TOLERANCE INVOLVE THE SAME MECHANISMS 
Until the last decade, a transplanted organ was viewed as 
a defenseless object of immune attack by the host, subject to 
rejection of varying severity depending on the degree of 
histoincompatibility (Figure 5, upper left). In contrast, the 
cytoablated host after bone marrow engraftment was viewed as 
the defenseless object of a unidirectional graft versus host 
(GVH) immune reaction (Figure 5, upper right). In the early 
1990s, we discovered evidence suggesting that both of these 
perceptions were incorrect, in that a double immune reaction 
occurred with both kinds of transplantation. This insight 
began with a study of long-term human survivors of liver, 
kidney and other organ transplantations. 
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It was discovered that all of these organ recipients had 
small numbers of donor leukocytes in their blood or tissue 
(microchimerism) (Starzl et al, 1992a, 1992b, 1993). At about 
the same time, it was shown that cytoablation of bone marrow 
recipients does not completely destroy host leukocytes 
(Przepiorka et al, 1991; Wessman et al, 1993) as had been 
previously assumed. From these findings, we concluded that a 
bidirectional immune reaction had taken place in both bone 
marrow and solid organ recipients, and that this occurred with 
maximum intensity in the first few post-transplant days or 
weeks (Figure 4) • The differences between organ 
transplantation and bone marrow transplantation (Table 5), 
which had been assumed for three decades to be caused by 
separate mechanisms, lay instead in the relative strength of 
the opposing immune reactions. Furthermore, reciprocal 
interactions of coexisting donor and recipient leukocyte 
populations were necessary for alloengraftment with both kinds 
of transplantation (Figure 5, lower). 
After organ transplantation, there is an acute migration 
of immunogenic mul tilineage "passenger" leukocytes from the 
graft, selectively at first to host lymphoid organs. In the 
meanwhile, host cells replaced most but not all of the 
passenger leukocytes in the graft (Figure 6). Initially, the 
coexisting donor and recipient cells in widespread organized 
lymphoid collections generate widespread host versus graft 
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(HVG) and graft versus host (GVH) immune activation that may 
proceed to reciprocal clonal exhaustion-deletion and variable 
degrees of donor and recipient speci fic non-reacti vi ty (i. e. 
tolerance) (Figure 4). Maintenance of the acutely induced 
state require persistence of the microchimerism (Starzl and 
Zinkernagel, 1998b; Ehl et al, 1998; Starzl, 1998a). The same 
events in mirror image occur with bone marrow engraftment. 
With either kind of transplantation, immunosuppression 
allowed the acute induction to proceed by preventing either 
the donor or recipient cell population from destroying the 
other before the clonal deletion could occur. The organs' 
passenger leukocytes that survive the initial immune reaction 
migrate secondarily to areas other than the lymphoid organs, 
thereby escaping attack by the host immune system (immune 
indifference) (Terakura et al, 1998) . These "sheltered" 
leukocytes may then \\ leak" periodically to the host lymphoid 
organs, thus maintaining clonal exhaustion-deletion at a level 
compatible with allograft survival (Starzl and Zinkernagel, 
1998b) (Figure 6). The greatest cell migration occurs from 
the leukocyte-rich liver, accounting for its unusual 
tolerogenicity; but the same events occur after 
transplantation of all organ grafts. The modulation of the 
host immune response by these donor cells explained the poor 
discrimination of HLA matching for organ transplantation. 
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THE IMMUNE REACTION TO INFECTIOUS 
MICROORGANISMS IS THE SAME AS THAT 
AGAINST ALLOGRAFTS AND XENOGRAFTS 
In 1974-75 Zinkernagel and Doherty discovered that one of 
the biologic roles of the maj or histocompatibility complex 
(MHC) is the adaptive immune response directed against 
noncytopathic or weakly intracellular 
microorganisms (Figure 7) • Because the cost 
cytopathic 
of total 
elimination of all cells infected with this kind of pathogen 
could be the death or invalidism of the host, a means has 
evol ved by which the· immune response can be terminated by 
antigen-specific clonal exhaustion-deletion, thereby allowing 
survival of both the microorganism and the host (Zinkernagel, 
1996) . Clonal deletion is governed by migration and 
localization of the microorganisms. In the same traffic 
pattern as that of migratory leukocytes, the pathogens move 
preferentially at 
(e. g. lymph nodes, 
first to host organized lymphoid tissues 
spleen) (Zinkernagel et al, 1997). After 
either an infection or after transplantation, host cytolytic T 
lymphocytes recognize the mobile antigen in a MHC-restricted 
context (Starzl and Zinkernagel, 1998b). 
Thus, a perfect state of allograft acceptance can be 
compared to a continuously high load of non-cytopathic 
microorganisms that may lead to a pathogen-specific 
immunologic collapse (i.e an asymptomatic carrier state) 
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(Figure 7, second panel). At the other extreme, acute 
irreversible rejection may be compared to dramatic, efficient 
control of the pathogen by antigen-specific effector T cells 
(Figure 7, first panel). Degrees of chronic rej ection of the 
allograft correspond to variable incomplete clonal exhaustion-
deletion (Figure 7, third panel). In mirror image, the 
infectious disease analogy with bone marrow transplantation 
after pretreatment with cytoablation is infection by 
microorganisms that avoid migration to host lymphoid organs 
(e.g. rabies and wart viruses) and therefore do not induce an 
efficient immune response (immune indifference) 
right) . 
In contrast to the MHC restricted 
noncytopathic organisms, the response to 
(Figure 7, 
response to 
cytopathic 
microorganisms includes activation of the innate response 
effectors such as interferons, macrophages, gamma/delta T 
cells, natural killer (NK) cells, B cells that may continue to 
secrete antibodies without T cell help, early interleukins and 
phagocytes (Zinkernagel, 1996). The principal but probably 
not the only target of this uncontrollable reaction when the 
organs of lower mammals (e. g. of pigs) are transplanted to 
humans is the galactose a 1-3 galactose epitope (aGal) found 
in the Golgi apparatus of the cells (Galili et ai, 1987; 
Cooper, Koren, and Oriol, 1994). If such discordant animal 
organs, or even those from more closely related species such 
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as baboons are to be transplanted clinically, it will be 
necessary to change the antigenic profile of the xenograft to 
one that is recognized by the human immune system as a non-
cytopathic microorganism (i. e. comparable to an allograft). 
Until this is accomplished by the creation of transgenic 
animals, xenotransplantation will not be a viable option. 
CONCLUSIONS 
Over the last 40 years, progress in manipulating the 
mechanisms involved in the immune response has steadily 
increased the probability of allograft acceptance and acquired 
tolerance. However, the penalty has been variable weakening of 
the host's ability to mount an immunologic response to 
pathogens, to maintain tumor surveillance, or (probably) to 
carry out other subtle homeostatic functions. Herein lies one 
of the primary challenges to the future of transplantation. 
Hopefully, from continued study of transplantation per se, as 
well as advances in related fields, more effective solutions 
will be found to overcome the current barriers to allografts 
or even xenografts with minimum perturbation to all other 
facets of immune function. 
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ORGAN 
Kidney 
Bone Marrow 
Liver 
Heart 
Pancreas * 
Lung * * 
Abdominal 
multivisceral*** 
Intestine alone 
TABLE 2: FIRST SUCCESSFUL TRANSPLANTATION OF • 
HUMAN ALLOGRAFTS (SURVIVAL > 6 MONTHS) 
CITY DATE PHYSICIAN/SURGEON 
(DATE PUBLISHED) 
Boston 1/24/59 Murray at al (1960) 
Paris 4/23/63 Mathe et al (1963) 
Denver 7/23/67 Starzl et al (1968) 
Cape Town 1/2/68 Barnard (1968) 
Minneapolis 6/3/69 Lillehei et al (1970) 
Ghent 11/14/68 Derom et al 
Pittsburgh 11/1/87 Starzl et al 
Paris 3/18/89 Goulet et al 
*Kidney and pancreas allografts in uremic patient. 
**Patient died after 10 months. The first> one 
year survival of isolated lung recipient was not 
reported until 1987 (Cooper et al 1990). 
***Small and large bowel plus liver, pancreas, stomach, 
and duodenum. The patient died after 6 months. 
(1971) 
(1989) 
(1992) 
TABLE 3 
KIDNEY TRANSPLANTATION 
~ 6 MONTHS SURVIVAL AS OF MARCH 1963 
Case City Date Donor Survival (months)+ 
1. Boston 1-24-59 Frat twin >50 
2. Paris 6-29-59 Frat twin >45 
3. Paris 6-22-60 Unrelated* 18 (Died) 
4. Paris 12-19-60 Mother* 12 (Died) 
5. Paris 3-12-61 Unrelated* 18 (Died) 
6. Paris 2-12-62 Cousin* >13 
7 . Boston 4-5-62 Unrelated 10 
*Adjunct steroid therapy 
+The kidneys in patients 1, 2, and 6 functioned for 20.5, 25, and 15 years 
respectively. Patient 7 rejected his graft after 17 months and died 7 
months after return to dialysis. 
Cases 1 and 7: Murray et al (1960, 1963) 
Cases 2, 4, and 6: Hamburger et al (1959, 1962) 
Cases 3 and 5: Kuss et al (1962) 
TABLE 4 
DIRECTION OF ACCEPTABLE ORGAN TRANSFER 
WHEN THE DONOR AND RECIPIENT HAVE 
DIFFERENT ABO RED CELL TYPES* (Starzl, 1964c) 
o to non-O Safe 
Rh- to Rh+ Safe 
Rh+ to Rh- Relatively safe 
A to non-A Dangerous 
B to non-B Dangerous 
AB to non-AB Dangerous 
*For organ transplantation, 0 is universal donor and AB is 
universal recipient. With the transplantation of bone marrow 
allografts, or of lymphoid rich organ allografts (e.g. intestine or 
liver), enough antihost isoagglutinins may be produced by the 
allograft to cause serious or lethal hemolysis in a significant 
number of cases (humoral GVHD). Consequently, the rules summarized 
in this table are fully applicable only with leukocyte-poor organs 
like the kidney and heart. 
TABLE 5 
DIFFERENCES BETWEEN CONVENTIONAL BONE MARROW 
AND ORGAN TRANSPLANTATION (Starzl and Zinkernaqel 1998b) 
Bone Marrow Orqan 
Yes <-- Recipient Cytoablation* --> No 
Critical <-- MHC Compatibility --> Not Critical 
GVHD <-- Principal Complication --> Rejection 
Common <-- Drug Free State --> Rare 
Tolerance <-- Term for Success --> "Acceptance"** 
*Note: All differences derive from this therapeutic step which in effect 
establishes an unopposed GVH reaction in the bone marrow recipient whose 
countervailing immune reaction is eliminated. 
**Or "operational tolerance" 
--------------------------------------------
FIGURE LEGENDS 
Figure 1 Hypothesis published in 1969 of allograft 
acceptance by clonal exhaustion. Antigen presentation was 
depicted via the macrophages rather than by the dendritic 
cells (which had not yet been described). A gap in this 
hypothesis was the failure to stipulate the location of the 
immune activation (Starzl 1969a) 
Figure 2 --- The historic concern that there would be 
simultaneous loss of host ractivity to specific strains of 
endogenous bacteria, as well as to the alien renal tissue. 
Figure 3 --- The 3 eras of orthotopic liver 
transplantation at the Universities of Colorado (1963-80) and 
Pittsburgh (1981-1993), defined by azathioprine (AZA) , 
cyclosporine (CYA), and tacrolimus/(TAC)-based immune 
suppression. Patient survival was about 10% higher than graft 
survival in both the cyclosporine (1980-89) and tacrolimus 
eras (1989-93) because of effective hepatic retransplantation, 
an option that did not exist previously. Similar stepwise 
improvements were seen with transplantation of all organs. 
Figure 4 --- Contemporaneous host versus graft (HVG) and 
graft versus host (GVH) reactions in the two-way paradigm of 
transplantation immunology. Following the initial interaction 
leading to clonal exhaustion-deletion, maintenance of the 
58 
exhaustion-deletion state is dependent on persistent donor 
leukocyte chimerism (see text and Figure 6). Thus, continued 
allograft acceptance/tolerance is depicted as a low-grade 
stimulatory state. 
Figure 5 --- (Top panels) One-way paradigm in which 
transplantation is conceived as involving a unidirectional 
immune reaction: (left) host-versus-graft (HVG) with whole 
organs and (right) graft-versus-host (GVH) with bone marrow or 
other lymphopoietic transplants. (Bottom panels) Two-way 
paradigm with which transplantation is seen as a bidirectional 
and mutually cancelling immune reaction that is (left) 
predominantly HVG with whole organ grafts, and (right) 
predominantly GVH with bone marrow grafts. 
Figure 6 --- The four events that occur in close temporal 
approximation when there is successful organ engraftment. 
Double acute clonal exhaustion (1,2). Maintenance of the 
clonal exhaustion-deletion requires persistence of donor 
leukocytes in recipient tissues (3) and in the allograft (4) 
The "accepted " allograft is never completely depleted of 
these donor cells and it serves as a preferential site for 
donor stem cells. 
Figure 7 --- Variable outcomes after infection with 
widely disseminated non-cytopathic viruses (or other 
59 
microorganisms} and analogies (text below the panels) to organ 
and bone marrow transplantation. The horizontal axis denotes 
time, and the vertical axis shows the viral load (blue line), 
and the host immune response (dashed red line) . 
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